PrEP Shortage to Ease as New Manufacturer Joins the Market

A major breakthrough in the HIV prevention medication PrEP Australian shortage is on the horizon.

The Australian Therapeutic Goods Administration (TGA) and the Pharmaceutical Benefits Scheme (PBS) have approved a new manufacturer, Laurus Labs, to help address the supply constraints that have been impacting availability for the past six weeks.

Health Equity Matters, the peak body for communities affected by HIV in Australia, has assured the community that PrEP supplies will soon return to normal levels.

James Gray, Principal Director of the Australia Program, advised individuals with sufficient medication to hold off on purchasing more until late October unless they are travelling or live in remote areas.

ASHM CEO Alexis Apostolellis echoed this sentiment, urging doctors to advise patients to delay filling scripts unless necessary.

For those in urgent need or travelling, importing PrEP through websites like PrEPaccessNow remains an option.

The shortage has prompted renewed discussions about alternative PrEP usage methods. On-demand and periodic use, which involve reduced medication consumption, are viable options for many individuals.

Community members are encouraged to consult with their GPs and explore resources like Emen8 to learn more about these alternatives.

The approval of Laurus Labs marks a significant step towards resolving the PrEP shortage and ensuring continued access to this vital HIV prevention tool.

With a return to normal supply expected by early November, the community can look forward to greater availability and peace of mind.

Last Updated on Oct 2, 2024